Wall Street analyst estimates for Praxis Precision Medicines, Inc. (PRAX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity.
Valuation Ratios
| Price / Book | 6.34 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $2.4M | $8.6M | 0 |
| Cost of Revenue | $1000 | $679000 | 0 | 0 | $154.4M | $86.8M | $152.4M | $140000 |
| Gross Profit | -$1000 | -$679000 | 0 | 0 | -$154.4M | -$84.3M | -$143.9M | -$140000 |
| Research & Development | $18.8M | $29.6M | $45.0M | $120.3M | $155.0M | $86.8M | $152.4M | $267.1M |
| Selling, General & Admin | $3.9M | $6.2M | $17.0M | $47.1M | $59.5M | $42.1M | $56.3M | $59.1M |
| Operating Expenses | $22.7M | $35.8M | $62.0M | $167.3M | $60.5M | $42.1M | $56.3M | $326.1M |
| Operating Income | -$22.7M | -$35.8M | -$62.0M | -$167.3M | -$215.0M | -$126.4M | -$200.2M | -$326.2M |
| EBITDA | -$26.3M | -$34.9M | -$61.9M | -$166.9M | -$213.6M | -$122.8M | -$182.5M | -$303.1M |
| Interest Expense | $127000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$26.4M | -$35.6M | -$61.8M | -$167.1M | -$214.0M | -$123.3M | -$182.8M | -$303.3M |
| Income Tax | $133000 | -$84000 | -$8000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$26.5M | -$35.5M | -$61.8M | -$167.1M | -$214.0M | -$123.3M | -$182.8M | -$303.3M |
| EPS | $-306.73 | $-348.24 | $-103.61 | $-58.96 | $-69.33 | $-18.69 | $-10.21 | $-13.48 |
| EPS (Diluted) | $-306.73 | $-348.24 | $-103.61 | $-58.96 | $-69.33 | $-18.69 | $-10.21 | $-13.48 |
| Shares Outstanding (Diluted) | $86509 | $101975 | $596677 | $2.8M | $3.1M | $6.6M | $17.9M | $22.5M |
Price
| Price | $308.99 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · AKRO · CNTA · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of PRAX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks